We demonstrated the important role of ALOX12–12-HETE-GPR31 in HCC recurrence, which may provide a potential therapeutic target to reduce the tumor recurrence in NAFLD after liver transplantation. This evidence concerns the gene GPR31 and metabolic dysfunction-associated steatotic liver disease.